Korea Research Institute of Bioscience and Biotechnology

Enzychem Lifesciences Corporation

Seoul National University

Yungjin Pharmaceutical Co., Ltd.

Su Ui Lee

Kyung Seop Ahn

Sei-Ryang Oh

Ki Young Sohn

In Sik Shin

Yong-Hae Han

Tae-Suk Lee

JongKoo Kang

Ok-Kyoung Kwon

Hyung Won Ryu

Young-Sik Jung

Na-Rae Shin

Ki-Hyun Kim

Sei Ryang Oh

Junho Chung

Hyeong Kyu Lee

Jung Hee Kim

Doo Young Kim

Hyori Kim

Doo-Young Kim

Dae-hee Shin

Yongnam Lee

In Pyo Choi

Kyung-seop Ahn

Seung Hyung Kim

Hye Kyung Kim

Hyun-Jun Lee

Sooyun Lee

Hyeong-Kyu Lee

Hyuk-Hwan Song

In-Sik Shin

Chan Mi Chun

Tae-Don Kim

Mun Ock Kim

Hyun Jae Jang

Byung-Hwan Ryoo

Ji-Seok Yoo

Jongkoo Kang

Hyeongkyu Lee

Kyung-Seop Ahn

Dae-Hee Shin

The present invention relates to a pharmaceutical composition for preventing or treating obesity or diabetes, and to a food composition and feed composition for preventing or alleviating obesity or diabetes, comprising as an active ingredient, anextract, aextract, or compounds isolated therefrom. The composition has synergistic antidiabetic and antiobesity activity compared to that of using only anextract, aextract, or compounds isolated therefrom. Therefore, it is possible to reduce the possibility of any side effects that may be caused by an overdose of or long-term administration of theextract and a substance isolated therefrom, and thus the composition can be very effectively utilized in the development of a therapeutic agent for diabetes or obesity.

Composition for preventing or treating obesity or diabetes, comprising acanthopanax senticosus extract and garcinia cambogia extract or compound isolated therefrom

Disclosed are a natural killer (NK) cell expressing an anti-cotinine chimeric antigen receptor (CAR) specifically binding to cotinine, and a cell therapeutic agent containing the NK cell. The CAR-expressing NK cell which specifically binds cotinine, can effectively move to tumor tissue, regardless of the kind of cancer, depending on the binding substance bound to cotinine. Therefore, the natural killer cell can be usefully employed as a gene therapy exhibiting a highly efficient anticancer effect.

Natural killer cell expressing anti-cotinine chimeric antigen receptor

The present invention relates to a pharmaceutical composition containing a monoacetyldiacyiglycerol compound as an active ingredient for preventing or treating asthma, and a functional health food composition for preventing or treating asthma. The monoacetyldiacylglycerol compound of the present invention inhibits the expression of IL-4 in EL-4 cells, which are mouse T cell lymphoma cells, reduces hypersensitivity of airway in an asthma-induced animal model, and inhibits the infiltration of inflammatory cells into the bronchial tube. In addition, the compounds of the present invention inhibit the generation of IgE in the serum and bronchoalveolar lavage fluid, have an excellent effect of inhibiting the expression of Th2 cytokines (IL-4, IL-5, and IL-13) in the lung, thereby overcome side effects of the currently used therapeutic agents for asthma, have no toxicity, and exhibit a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating asthma.

Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating asthma

The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating chronic obstructive pulmonary diseases, and a functional health food composition for treating or preventing chronic obstructive pulmonary diseases. The monoacetyldiacylglycerol compound of the present invention inhibits the IL-4 expression in EL-4 cells and inhibits the infiltration of inflammatory cells into the bronchial tube in an animal model. In addition, the compounds of the present invention have an excellent effect of inhibiting the expression of CXCL-1, TNF-&#x3b1;, or MIP-2, thereby overcoming side effects of the currently used therapeutic agents for chronic obstructive pulmonary diseases, having no toxicity, and exhibiting a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating chronic obstructive pulmonary diseases.

Composition containing monoacetyldiglyceride compound as active ingredient for preventing or treating chronic obstructive pulmonary disease

A pharmaceutical composition includes any of an extract of, a fraction or an active fraction obtained by fractionation thereof with an organic solvent, and a compound separated therefrom as an active ingredient. The extract of, the fraction or the active fraction obtained by fractionation thereof with an organic solvent, or the compound separated therefrom inhibits the expression of MUC5AC induced by TNF-&#x3b1; and the promoter activity in human lung cancer mucosal cells (H292), reduces the number of inflammatory cells in the bronchoalveolar lavage fluid of the chronic obstructive pulmonary disease mouse model, inhibits the production of reactive oxygen species, and reduces the cytokines; and therefore are effective in preventing or treating chronic obstructive pulmonary disease.

Pharmaceutical composition for preventing and treating chronic obstructive lung disease containing, as active ingredient,extract, fraction, or active fraction thereof

The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating asthma, and a functional health food composition for preventing or treating asthma. The monoacetyldiacylglycerol compound of the present invention inhibits the expression of IL-4 in EL-4 cells, which are mouse T cell lymphoma cells, reduces hypersensitivity of airway in an asthma-induced animal model, and inhibits the infiltration of inflammatory cells into the bronchial tube. In addition, the compounds of the present invention inhibit the generation of IgE in the serum and bronchoalveolar lavage fluid, have an excellent effect of inhibiting the expression of Th2 cytokines (IL-4, IL-5, and IL-13) in the lung, thereby overcome side effects of the currently used therapeutic agents for asthma, have no toxicity, and exhibit a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating asthma.

Growing community of inventors

Daejeon, South Korea

Su Ui Lee